China SXT Pharmaceuticals Inc (NASDAQ:SXTC) — Market Cap & Net Worth
Market Cap & Net Worth: China SXT Pharmaceuticals Inc (SXTC)
China SXT Pharmaceuticals Inc (NASDAQ:SXTC) has a market capitalization of $2.36 Million ($2.36 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29781 globally and #5995 in its home market, demonstrating a -81.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China SXT Pharmaceuticals Inc's stock price $0.06 by its total outstanding shares 38218077 (38.22 Million). See SXTC capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
China SXT Pharmaceuticals Inc Market Cap History: 2019 to 2026
China SXT Pharmaceuticals Inc's market capitalization history from 2019 to 2026. Data shows change from $3.13 Billion to $2.36 Million (-70.06% CAGR).
Index Memberships
China SXT Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #878 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2785 of 3165 |
Weight: China SXT Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
China SXT Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China SXT Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.20x
China SXT Pharmaceuticals Inc's market cap is 2.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $3.13 Billion | $7.01 Million | $1.54 Million | 446.93x | 2036.01x |
| 2020 | $1.26 Billion | $5.16 Million | -$10.29 Million | 243.57x | N/A |
| 2021 | $621.04 Million | $4.78 Million | -$2.75 Million | 129.99x | N/A |
| 2022 | $517.85 Million | $2.60 Million | -$5.74 Million | 199.00x | N/A |
| 2023 | $151.73 Million | $1.97 Million | -$5.93 Million | 76.95x | N/A |
| 2024 | $19.42 Million | $1.93 Million | -$3.10 Million | 10.07x | N/A |
| 2025 | $61.15 Million | $1.74 Million | -$3.30 Million | 35.12x | N/A |
| 2026 | $2.36 Million | $1.07 Million | -$6.21 Million | 2.20x | N/A |
Competitor Companies of SXTC by Market Capitalization
Companies near China SXT Pharmaceuticals Inc in the global market cap rankings as of August 1, 2026.
Key companies related to China SXT Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
China SXT Pharmaceuticals Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, China SXT Pharmaceuticals Inc's market cap moved from $3.13 Billion to $ 2.36 Million, with a yearly change of -70.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.36 Million | -96.14% |
| 2025 | $61.15 Million | +214.90% |
| 2024 | $19.42 Million | -87.20% |
| 2023 | $151.73 Million | -70.70% |
| 2022 | $517.85 Million | -16.62% |
| 2021 | $621.04 Million | -50.61% |
| 2020 | $1.26 Billion | -59.88% |
| 2019 | $3.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of China SXT Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.36 Million USD |
| MoneyControl | $2.36 Million USD |
| MarketWatch | $2.36 Million USD |
| marketcap.company | $2.36 Million USD |
| Reuters | $2.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu,… Read more